Drug of Abuse (DOA) Testing-Global Market Status & Trend Report 2015-2026 Top 20 Countries Data

Table Of Contents

Chapter 1 Overview of Drug of Abuse (DOA) Testing 1.1 Definition of Drug of Abuse (DOA) Testing in This Report 1.2 Commercial Types of Drug of Abuse (DOA) Testing 1.2.1 Urine 1.2.2 Saliva 1.2.3 Hair 1.2.4 Others 1.3 Downstream Application of Drug of Abuse (DOA) Testing 1.3.1 Hospitals 1.3.2 Laboratories 1.3.3 Workplace 1.3.4 At-Home 1.3.5 Others 1.4 Development History of Drug of Abuse (DOA) Testing 1.5 Market Status and Trend of Drug of Abuse (DOA) Testing 2015-2026 1.5.1 Global Drug of Abuse (DOA) Testing Market Status and Trend 2015-2026 1.5.2 Regional Drug of Abuse (DOA) Testing Market Status and Trend 2015-2026Chapter 2 Global Market Status and Forecast by Regions 2.1 Market Development of Drug of Abuse (DOA) Testing 2015-2019 2.2 Sales Market of Drug of Abuse (DOA) Testing by Regions 2.2.1 Sales Volume of Drug of Abuse (DOA) Testing by Regions 2.2.2 Sales Value of Drug of Abuse (DOA) Testing by Regions 2.3 Production Market of Drug of Abuse (DOA) Testing by Regions 2.4 Global Market Forecast of Drug of Abuse (DOA) Testing 2020-2026 2.4.1 Global Market Forecast of Drug of Abuse (DOA) Testing 2020-2026 2.4.2 Market Forecast of Drug of Abuse (DOA) Testing by Regions 2020-2026Chapter 3 Global Market Status and Forecast by Types 3.1 Sales Volume of Drug of Abuse (DOA) Testing by Types 3.2 Sales Value of Drug of Abuse (DOA) Testing by Types 3.3 Market Forecast of Drug of Abuse (DOA) Testing by TypesChapter 4 Global Market Status and Forecast by Downstream Industry 4.1 Global Sales Volume of Drug of Abuse (DOA) Testing by Downstream Industry 4.2 Global Market Forecast of Drug of Abuse (DOA) Testing by Downstream IndustryChapter 5 North America Market Status by Countries, Type, Manufacturers and Downstream Industry 5.1 North America Drug of Abuse (DOA) Testing Market Status by Countries 5.1.1 North America Drug of Abuse (DOA) Testing Sales by Countries (2015-2019) 5.1.2 North America Drug of Abuse (DOA) Testing Revenue by Countries (2015-2019) 5.1.3 United States Drug of Abuse (DOA) Testing Market Status (2015-2019) 5.1.4 Canada Drug of Abuse (DOA) Testing Market Status (2015-2019) 5.1.5 Mexico Drug of Abuse (DOA) Testing Market Status (2015-2019) 5.2 North America Drug of Abuse (DOA) Testing Market Status by Manufacturers 5.3 North America Drug of Abuse (DOA) Testing Market Status by Type (2015-2019) 5.3.1 North America Drug of Abuse (DOA) Testing Sales by Type (2015-2019) 5.3.2 North America Drug of Abuse (DOA) Testing Revenue by Type (2015-2019) 5.4 North America Drug of Abuse (DOA) Testing Market Status by Downstream Industry (2015-2019)Chapter 6 Europe Market Status by Countries, Type, Manufacturers and Downstream Industry 6.1 Europe Drug of Abuse (DOA) Testing Market Status by Countries 6.1.1 Europe Drug of Abuse (DOA) Testing Sales by Countries (2015-2019) 6.1.2 Europe Drug of Abuse (DOA) Testing Revenue by Countries (2015-2019) 6.1.3 Germany Drug of Abuse (DOA) Testing Market Status (2015-2019) 6.1.4 UK Drug of Abuse (DOA) Testing Market Status (2015-2019) 6.1.5 France Drug of Abuse (DOA) Testing Market Status (2015-2019) 6.1.6 Italy Drug of Abuse (DOA) Testing Market Status (2015-2019) 6.1.7 Russia Drug of Abuse (DOA) Testing Market Status (2015-2019) 6.1.8 Spain Drug of Abuse (DOA) Testing Market Status (2015-2019) 6.1.9 Benelux Drug of Abuse (DOA) Testing Market Status (2015-2019) 6.2 Europe Drug of Abuse (DOA) Testing Market Status by Manufacturers 6.3 Europe Drug of Abuse (DOA) Testing Market Status by Type (2015-2019) 6.3.1 Europe Drug of Abuse (DOA) Testing Sales by Type (2015-2019) 6.3.2 Europe Drug of Abuse (DOA) Testing Revenue by Type (2015-2019) 6.4 Europe Drug of Abuse (DOA) Testing Market Status by Downstream Industry (2015-2019)Chapter 7 Asia Pacific Market Status by Countries, Type, Manufacturers and Downstream Industry 7.1 Asia Pacific Drug of Abuse (DOA) Testing Market Status by Countries 7.1.1 Asia Pacific Drug of Abuse (DOA) Testing Sales by Countries (2015-2019) 7.1.2 Asia Pacific Drug of Abuse (DOA) Testing Revenue by Countries (2015-2019) 7.1.3 China Drug of Abuse (DOA) Testing Market Status (2015-2019) 7.1.4 Japan Drug of Abuse (DOA) Testing Market Status (2015-2019) 7.1.5 India Drug of Abuse (DOA) Testing Market Status (2015-2019) 7.1.6 Southeast Asia Drug of Abuse (DOA) Testing Market Status (2015-2019) 7.1.7 Australia Drug of Abuse (DOA) Testing Market Status (2015-2019) 7.2 Asia Pacific Drug of Abuse (DOA) Testing Market Status by Manufacturers 7.3 Asia Pacific Drug of Abuse (DOA) Testing Market Status by Type (2015-2019) 7.3.1 Asia Pacific Drug of Abuse (DOA) Testing Sales by Type (2015-2019) 7.3.2 Asia Pacific Drug of Abuse (DOA) Testing Revenue by Type (2015-2019) 7.4 Asia Pacific Drug of Abuse (DOA) Testing Market Status by Downstream Industry (2015-2019)Chapter 8 Latin America Market Status by Countries, Type, Manufacturers and Downstream Industry 8.1 Latin America Drug of Abuse (DOA) Testing Market Status by Countries 8.1.1 Latin America Drug of Abuse (DOA) Testing Sales by Countries (2015-2019) 8.1.2 Latin America Drug of Abuse (DOA) Testing Revenue by Countries (2015-2019) 8.1.3 Brazil Drug of Abuse (DOA) Testing Market Status (2015-2019) 8.1.4 Argentina Drug of Abuse (DOA) Testing Market Status (2015-2019) 8.1.5 Colombia Drug of Abuse (DOA) Testing Market Status (2015-2019) 8.2 Latin America Drug of Abuse (DOA) Testing Market Status by Manufacturers 8.3 Latin America Drug of Abuse (DOA) Testing Market Status by Type (2015-2019) 8.3.1 Latin America Drug of Abuse (DOA) Testing Sales by Type (2015-2019) 8.3.2 Latin America Drug of Abuse (DOA) Testing Revenue by Type (2015-2019) 8.4 Latin America Drug of Abuse (DOA) Testing Market Status by Downstream Industry (2015-2019)Chapter 9 Middle East and Africa Market Status by Countries, Type, Manufacturers and Downstream Industry 9.1 Middle East and Africa Drug of Abuse (DOA) Testing Market Status by Countries 9.1.1 Middle East and Africa Drug of Abuse (DOA) Testing Sales by Countries (2015-2019) 9.1.2 Middle East and Africa Drug of Abuse (DOA) Testing Revenue by Countries (2015-2019) 9.1.3 Middle East Drug of Abuse (DOA) Testing Market Status (2015-2019) 9.1.4 Africa Drug of Abuse (DOA) Testing Market Status (2015-2019) 9.2 Middle East and Africa Drug of Abuse (DOA) Testing Market Status by Manufacturers 9.3 Middle East and Africa Drug of Abuse (DOA) Testing Market Status by Type (2015-2019) 9.3.1 Middle East and Africa Drug of Abuse (DOA) Testing Sales by Type (2015-2019) 9.3.2 Middle East and Africa Drug of Abuse (DOA) Testing Revenue by Type (2015-2019) 9.4 Middle East and Africa Drug of Abuse (DOA) Testing Market Status by Downstream Industry (2015-2019)Chapter 10 Market Driving Factor Analysis of Drug of Abuse (DOA) Testing 10.1 Global Economy Situation and Trend Overview 10.2 Drug of Abuse (DOA) Testing Downstream Industry Situation and Trend OverviewChapter 11 Drug of Abuse (DOA) Testing Market Competition Status by Major Manufacturers 11.1 Production Volume of Drug of Abuse (DOA) Testing by Major Manufacturers 11.2 Production Value of Drug of Abuse (DOA) Testing by Major Manufacturers 11.3 Basic Information of Drug of Abuse (DOA) Testing by Major Manufacturers 11.3.1 Headquarters Location and Established Time of Drug of Abuse (DOA) Testing Major Manufacturer 11.3.2 Employees and Revenue Level of Drug of Abuse (DOA) Testing Major Manufacturer 11.4 Market Competition News and Trend 11.4.1 Merger, Consolidation or Acquisition News 11.4.2 Investment or Disinvestment News 11.4.3 New Product Development and LaunchChapter 12 Drug of Abuse (DOA) Testing Major Manufacturers Introduction and Market Data 12.1 Siemens 12.1.1 Company profile 12.1.2 Representative Drug of Abuse (DOA) Testing Product 12.1.3 Drug of Abuse (DOA) Testing Sales, Revenue, Price and Gross Margin of Siemens 12.2 Psychemedics 12.2.1 Company profile 12.2.2 Representative Drug of Abuse (DOA) Testing Product 12.2.3 Drug of Abuse (DOA) Testing Sales, Revenue, Price and Gross Margin of Psychemedics 12.3 Thermo Fisher Scientific 12.3.1 Company profile 12.3.2 Representative Drug of Abuse (DOA) Testing Product 12.3.3 Drug of Abuse (DOA) Testing Sales, Revenue, Price and Gross Margin of Thermo Fisher Scientific 12.4 Merck 12.4.1 Company profile 12.4.2 Representative Drug of Abuse (DOA) Testing Product 12.4.3 Drug of Abuse (DOA) Testing Sales, Revenue, Price and Gross Margin of Merck 12.5 Quest Diagnostics 12.5.1 Company profile 12.5.2 Representative Drug of Abuse (DOA) Testing Product 12.5.3 Drug of Abuse (DOA) Testing Sales, Revenue, Price and Gross Margin of Quest Diagnostics 12.6 Roche 12.6.1 Company profile 12.6.2 Representative Drug of Abuse (DOA) Testing Product 12.6.3 Drug of Abuse (DOA) Testing Sales, Revenue, Price and Gross Margin of Roche 12.7 Abbott 12.7.1 Company profile 12.7.2 Representative Drug of Abuse (DOA) Testing Product 12.7.3 Drug of Abuse (DOA) Testing Sales, Revenue, Price and Gross Margin of Abbott 12.8 Bio-Rad 12.8.1 Company profile 12.8.2 Representative Drug of Abuse (DOA) Testing Product 12.8.3 Drug of Abuse (DOA) Testing Sales, Revenue, Price and Gross Margin of Bio-RadChapter 13 Upstream and Downstream Market Analysis of Drug of Abuse (DOA) Testing 13.1 Industry Chain of Drug of Abuse (DOA) Testing 13.2 Upstream Market and Representative Companies Analysis 13.3 Downstream Market and Representative Companies AnalysisChapter 14 Cost and Gross Margin Analysis of Drug of Abuse (DOA) Testing 14.1 Cost Structure Analysis of Drug of Abuse (DOA) Testing 14.2 Raw Materials Cost Analysis of Drug of Abuse (DOA) Testing 14.3 Labor Cost Analysis of Drug of Abuse (DOA) Testing 14.4 Manufacturing Expenses Analysis of Drug of Abuse (DOA) TestingChapter 15 Report ConclusionChapter 16 Research Methodology and Reference 16.1 Methodology/Research Approach 16.1.1 Research Programs/Design 16.1.2 Market Size Estimation 16.1.3 Market Breakdown and Data Triangulation 16.2 Data Source 16.2.1 Secondary Sources 16.2.2 Primary Sources 16.3 Reference